Thymidylate synthase expression in normal colonic mucosa: A predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy

Oncology

Volumn 67, Issue 2, 2004, Pages 135-142

  Santini, Daniele ^a   Vincenzi, Bruno ^a,b   Perrone, Giuseppe ^b   Rabitti, Carla ^b   Borzomati, Domenico ^b   Caricato, Marco ^b   La Cesa, Annalisa ^a   Grilli, Claudia ^a   Verzì, Alfio ^b   Coppola, Roberto ^b   Tonini, Giuseppe ^a  

^a Medical Oncology   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

5 Fluorouracil; Colorectal cancer; Thymidylate synthase; Toxicity

Indexed keywords

BIOCHEMICAL MARKER; FLUOROURACIL; FOLINIC ACID; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DISEASE MARKER; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; STOMATITIS; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 8344245563     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081000     Document Type: Article

References (38)

1. Kaneda S, Takeishi K, Ayusawa D, Shimizu K, Seno T, Altman S: Role in translation of a triple tandemly repeated sequence in the 5′-untranslated region of human thymidylate synthase mRNA. Nucleic Acids Res 1987;15:1259-1270.
2. Kawakami K, Salonga D, Park JM, Danenberg KD, Uetake H, Brabender J, Omura K, Watanabe G, Danenberg PV: Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 2001;7:4096-4101.
3. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995;20:191-197.
4. Etienne MC, Chazal M, Laurent-Puig P, Magne N, Rosty C, Formento JL, Francoual M, Formento P, Renee N, Chamorey E, Bourgeon A, Seitz JF, Delpero JR, Letoublon C, Pezet D, Milano G: Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: Phenotypic and genotypic analyses. J Clin Oncol 2002;20:2832-2843.
5. Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP, Leichman CG: p53 mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival. Clin Cancer Res 1998;4:1243-1250.
6. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA, Allegra CJ: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2640-2647.
7. Yamachika T, Nakanishi H, Inada K, Tsukamoto T, Kato T, Fukushima M, Inoue M, Tatematsu M: A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 1998;82:70-77.
8. Takenoue T, Nagawa H, Matsuda K, Fujii S, Nita ME, Hatano K, Kitayama J, Tsuruo T, Muto T: Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol 2000;7:193-198.
9. Edler D, Hallstrom M, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H: Thymidylate synthase expression: An independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res 2000;6:1378-1384.
10. Edler D, Kressner U, Ragnhammar P, Johnston PG, Magnusson I, Glimelius B, Pahlman L, Lindmark G, Blomgren H: Immunohistochemically detected thymidylate synthase in colorectal cancer: An independent prognostic factor of survival. Clin Cancer Res 2000;6:488-492.
11. Bathe OF, Franceschi D, Livingstone AS, Moffat FL, Tian E, Ardalan B: Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: Implications for chemotherapeutic options and survival. Cancer J Sci Am 1999;5:34-40.
12. Johnston PG, Allegra CJ: Colorectal cancer biology: Clinical implications. Semin Oncol 1995;22:418-432.
13. Brohee D: 5-Fluorouracil and folinic acid in the treatment of advanced colorectal cancer: An updated meta-analysis. Med Sci Res 1994;22:383-384.
14. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 1998;16:3537-3541.
15. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, Delva RG, Lortholary AH, Gesta PH, Larra FG: Relationship between 5-fluorouracil dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996;77:441-451.
16. Trump DL, Egorin MJ, Forrest A, Willson JK, Remick S, Tutsch KD: Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol 1991;9:2027-2035.
17. Santini J, Milano G, Thyss A, Renee N, Viens P, Ayela P, Schneider M, Demard F: 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 1989;59:287-290.
18. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, Schneider M, Demard F, Milano G: Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994;12:2248-2253.
19. Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993;53:5433-5438.
20. Diasio RB, Beavers TL, Carpenter JT: Familial deficiency of dihydropyrimidine dehydrogenase: Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988;81:47-51.
21. Raida M, Schwabe W, Hausler P, Van Kuilenburg AB, Van Gennip AH, Behnke D, Hoffken K: Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 2001;7:2832-2839.
22. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-1418.
23. Morson BC, Dawson IM, Day DW, et al: Grading classification according to WHO; in Morson BC, Dawson IM (eds): Morson and Dawson's Gastrointestinal Pathology, ed 3. Oxford, Blackwell Scientific, 1990, pp 67-77.
24. Edler D, Blomgren H, Allegra CJ, Johnston PG, Lagerstedt U, Magnusson I, Ragnhammar P: Immunohistochemical determination of thymidylate synthase in colorectal cancer - Methodological studies. Eur J Cancer 1997;33:2278-2281.
25. Corsi DC, Ciaparrone M, Zannoni G, Mancini M, Cassano A, Specchia M, Pozzo C, Martini M, Barone C: Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer. Eur J Cancer 2002;38:527-534.
26. Leichman L, Lenz HJ, Leichman CG, Groshen S, Danenberg K, Baranda J, Spears CP, Boswell W, Silberman H, Ortega A, et al: Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: Preliminary report from an ongoing trial. Eur J Cancer 1995;31:1306-1310.
27. Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, Lionetto R, Maley F, Sobrero A: Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 1999;17:1760-1770.
28. Cascinu S, Aschele C, Barni S, Debernardis D, Baldo C, Tunesi G, Catalano V, Staccioli MP, Brenna A, Muretto P, Catalano G: Thymidylate synthase protein expression in advanced colon cancer: Correlation with the site of metastasis and the clinical response to leucovorinmodulated bolus 5-fluorouracil. Clin Cancer Res 1999;5:1996-1999.
29. Davies MM, Johnston PG, Kaur S, Allen-Mersh TG: Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine. Clin Cancer Res 1999;5:325-328.
30. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M, Danenberg PV: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protractedinfusion fluorouracil and weekly leucovorin. J Clin Oncol 1997;15:3223-3229.
31. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55:1407-1412.
32. Edler D, Glimelius B, Hallstrom M, Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H: Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002;20:1721-1728.
33. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19:4298-4304.
34. Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic I, Martinez E, Illarramendi JJ, Arias F, Martinez Monge R, Salgado E, Angeletti S, Brugarolas A: Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001;19:1779-1786.
35. Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993;53:5433-5438.
36. Diasio RB, Beavers TL, Carpenter JT: Familial deficiency of dihydropyrimidine dehydrogenase: Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988;81:47-51.
37. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S, Lenz HJ: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001;1:65-70.
38. van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, Baas F, Richel DJ, van Gennip AH: Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: Frequency of the common IVS14 + 1G>A mutation causing DPD deficiency. Clin Cancer Res 2001;7:1149-1153.